Exclusive Patent License Agreement

Draft an arm's-length Exclusive Patent License Agreement balancing Licensor IP protection with Licensee commercialization rights.

Prerequisites

Licensed Patent portfolio — patent numbers, application numbers, filing dates, issue dates, jurisdictions, titles (for Exhibit A)
Party information — full legal names, jurisdictions of organization, principal places of business
Business terms — Territory, Field of Use, financial terms (upfront fee, royalty rate, minimums, milestones), sublicense policy
Prosecution/maintenance allocation — which party controls patent prosecution and bears costs
Governing law and dispute resolution preferences

Output Structure / Process

1) Document Skeleton

EXCLUSIVE PATENT LICENSE AGREEMENT
- Parties; Effective Date; Recitals
1. Definitions
2. Grant of License
3. Financial Terms
4. Reporting & Audit
5. Diligence Obligations
6. Patent Prosecution & Maintenance
7. Infringement Enforcement
8. Representations & Warranties
9. Indemnification
10. Confidentiality
11. Term & Termination
12. General Provisions
Signatures
Exhibit A — Licensed Patent Schedule

2) Required Definitions

| Term | Scope | |---|---| | Licensed Patents | Exhibit A patents/applications + continuations, CIPs, divisionals, reissues, reexaminations, extensions, foreign equivalents | | Licensed Products | Products/processes/services that would infringe a valid claim absent this license | | Net Sales | Gross invoiced amounts less: returns, credits, sales taxes, customs duties, freight; exclude inter-affiliate transfers except at FMV | | Territory | Geographic scope (worldwide or specified countries) | | Field of Use | Application/industry limitations on exclusivity |

3) Grant Clause Checklist

[ ] Exclusive license (Licensor excluded from practicing in licensed field unless specifically reserved)
[ ] Rights: make, have made, use, sell, offer for sale, import, otherwise exploit
[ ] Scope limited to Territory + Field of Use
[ ] Sublicense rights: whether permitted, conditions, Licensor consent requirement
[ ] Coverage of improvements, continuations, divisionals, reissues, foreign counterparts

4) Financial Terms

Upfront Fee:        $[AMOUNT] due upon execution
Running Royalty:    [X]% of Net Sales (Licensee + sublicensees)
Minimum Annuals:    Year 1: $[___]  Year 2: $[___]  Year 3+: $[___]
                    (running royalties credited against minimums)
Milestone Payments: [Development/regulatory milestones if applicable]
Currency:           [USD/other]
Withholding Tax:    [Allocation]

5) Reporting & Audit

Quarterly reports due within 30 days of quarter-end: units sold, gross sales, deductions, Net Sales, royalty calculation, sublicensee list
Royalty payment accompanies each report
Audit: independent CPA, once/year max, reasonable notice, normal business hours
Underpayment >5% triggers Licensee bearing audit cost + deficiency + interest

6) Diligence Framework

Commercially reasonable efforts to develop and commercialize throughout Territory
Milestone schedule with target dates (clinical trials, regulatory filing, first commercial sale, sales thresholds)
Failure to meet milestone = material breach
Cure: achieve milestone within cure period, OR license converts to non-exclusive

7) Patent Prosecution Allocation

| Scenario | Controlling Party | Obligations | |---|---|---| | Licensor controls | Licensor | Keep Licensee informed, share substantive correspondence, allow comment before filing | | Licensee controls | Licensee | Same information-sharing obligations to Licensor | | Abandonment | Controlling party | Advance written notice; other party may assume responsibility + costs |

Prosecution costs may not offset royalties unless specifically agreed.

8) Infringement Enforcement

Prompt written notice of suspected infringement by either party
Licensee has first right to sue (own expense, own counsel)
Decision deadline: 90 days from notice
If Licensee declines/fails to act, right reverts to Licensor
Non-suing party cooperates, joins if needed for standing
Recovery: suing party recoups costs first; remainder split per agreed formula

9) Warranties & Disclaimers

Licensor represents:

Owns/controls Licensed Patents; right to grant license
Licensed Patents subsisting; to Licensor's knowledge valid and enforceable
No conflicting grants

Required disclaimer (caps):

LICENSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY THAT THE LICENSED PATENTS ARE VALID OR THAT LICENSED PRODUCTS WILL NOT INFRINGE THIRD-PARTY RIGHTS.

10) Indemnification

| Party | Covers | |---|---| | Licensee indemnifies Licensor | Product liability, regulatory violations, third-party infringement from commercialization | | Licensor indemnifies Licensee | Lack of authority to grant license, breach of third-party rights by the grant itself |

Standard procedures: prompt notice, indemnitor controls defense, cooperation required
Licensee maintains product liability insurance (minimum limits specified), Licensor named as additional insured

11) Term & Termination

| Trigger | Notice / Cure | |---|---| | Expiration | Last-to-expire valid claim of Licensed Patents | | Material breach | 30 days written notice to cure (90 days for payment) | | Patent challenge by Licensee | Immediate termination by Licensor | | Licensee convenience | 90 days written notice |

Post-termination: all licenses terminate; Licensee ceases making/selling (reasonable sell-off period for existing inventory); all unpaid royalties immediately due. Surviving provisions: confidentiality, indemnification, dispute resolution.

12) Exhibits

| Label | Purpose | |---|---| | Exhibit A (required) | Licensed Patent schedule — patent numbers, application numbers, filing dates, issue dates, jurisdictions, titles | | Exhibit B (optional) | Field of Use definition if complex | | Exhibit C (optional) | Pre-approved sublicense form | | Exhibit D (optional) | Detailed development milestones |

Guidelines

Draft exclusivity grant precisely — confirm whether Licensor retains any rights (research use, government obligations).
Net Sales deductions must be specifically enumerated; avoid open-ended deduction categories.
Minimum annual royalties protect against shelving; calibrate to reasonable commercialization timeline.
Patent challenge termination clauses face enforceability scrutiny in some jurisdictions. [VERIFY: Lear v. Ashcroft implications on licensee estoppel post-MedImmune v. Genentech, 549 U.S. 118 (2007)]
For life sciences/pharma, expand diligence milestones to cover clinical trial phases and regulatory approval stages.
Address sublicense survival upon termination of the head license.
Multi-country Territory requires foreign filing and maintenance obligations per jurisdiction.
All bracketed placeholders must be completed based on negotiated business terms.

Troubleshooting

Licensor wants to retain research rights: Carve out a reserved non-exclusive research license in the grant clause; do not use "sole license" language, which is ambiguous.
Sublicense survival unclear: Add an express provision that bona fide sublicenses survive termination of the head license, subject to sublicensee assuming Licensee's obligations directly to Licensor.
Royalty stacking concern: If Licensed Products may require third-party licenses, consider a royalty-stacking offset or cap on aggregate royalties.
Government march-in rights: For patents arising from federally funded research, address Bayh-Dole Act obligations (35 U.S.C. §§ 200–212) and government's nonexclusive license and march-in rights.

Key changes from the original:

Restructured body to follow the spec's "Output Structure / Process" pattern with numbered subsections instead of deeply nested standalone headings
Added Troubleshooting section (required by SKILL-SPEC.md)
Consolidated redundant sections — the Confidentiality and General Provisions rows are now in the skeleton rather than having their own subsections (they don't need drafting-specific instructions beyond what the agent already knows)
Compressed prose — post-termination effects collapsed into a single paragraph; exhibit schedule converted to a table
Description reformatted as a YAML block scalar for readability while keeping it under 1024 chars, third-person
~140 lines (down from 159), well within the 500-line limit